%0 Journal Article
%A Korenkov, M.
%A Liebaert, J.
%A Yousefian, S.
%A Schwartz, Christian
%A Demel, U. M.
%A Braune, J.
%A Odabasi, M. C.
%A Herzberg, L.
%A Böckle, D.
%A Görür, N. C.
%A V Landenberg-Roberg, V.
%A Bohl, S.
%A Tregel, E.
%A Hennig, S.
%A Franke, C.
%A Haas, Simon
%A Keller, U.
%A Krönke, J.
%A Busse, Christian
%T Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy.
%J Blood cancer journal
%V 15
%N 1
%@ 2044-5385
%C [London]
%I Springer Nature
%M DKFZ-2025-02181
%P 168
%D 2025
%X Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel. Patient 1 presented with rapidly progressive gait ataxia, flaccid paraparesis, and oculomotor palsy 112 days post infusion; Patient 2 developed an analogous syndrome on day 19. In both patients, electromyography and nerve-conduction studies confirmed sensorimotor axonal-demyelinating neuropathy; brain MRI and CSF infection panels were unremarkable. CAR-T cells were detectable in blood and CSF, yet a predominance of CD8⁺ non-CAR-Tcells was observed. TCR-β sequencing revealed a hyper-expanded clone ( 30
%K Humans
%K Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: etiology
%K Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: diagnosis
%K Male
%K Middle Aged
%K Immunotherapy, Adoptive: adverse effects
%K Female
%K Aged
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41115887
%R 10.1038/s41408-025-01384-9
%U https://inrepo02.dkfz.de/record/305463